Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
April 20, 2009
- Takara Bio Obtains License from Kyoto Univ.
April 20, 2009
- Eli Lilly Licenses Cialis to Nippon Shinyaku
April 20, 2009
- GE, Intel Ally in Home Health Technologies
April 20, 2009
- Otsuka, BMS Extend Agreement on Abilify, Embark on Global Oncology Collaboration
April 20, 2009
- Olympus Releases Biliary Stent Jointly with Medinol
April 20, 2009
- Pfizer Aims to Become Market Leader for Macrolides with Zithromac SR
April 20, 2009
- AMDD Inaugurated with Dr H. Wang as President
April 20, 2009
- Hisamitsu: Both Sales and Profits Up 8th Year in a Row
April 20, 2009
- Agilent Technologies Launch SurePrint G3 Microarray
April 20, 2009
- Merck Serono: Gonalef Subcutaneous Injection Pen
April 20, 2009
- Eisai Licenses Out Gliadel Wafer to Nobelpharma
April 20, 2009
- BUSINESS NEWS IN BRIEF
April 20, 2009
- Asahi Kasei to Globally Develop Business for Evaheart
April 20, 2009
- Shiro Kondo Recognized as Teijin Group Fellow for His Contribution to the Development of Febuxostat
April 20, 2009
- Leadership Changes at KYORIN
April 20, 2009
- R&D NEWS IN BRIEF
April 20, 2009
- OHARA to Improve Tablet Distinguishability by ID Printing on Both Sides of Tablet
April 20, 2009
- So-net M3 Survey Shows Physicians Depend on Internet for Information
April 20, 2009
- JPDSC to Construct PGx Database for the Japanese
April 20, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…